(2)
Lonza Signs Agreement to Divest Specialty Ingredients Business to Bain Capital and Cinven
Lonza Specialty Ingredients to be sold to Bain Capital and Cinven for an enterprise value of CHF 4.2 billion
Divestment will allow Lonza to refocus its business as a pure-play partner to the healthcare industry
Successful track record of investment in industrials sector and portfolio companies confirms that Bain Capital and Cinven are the right home for the business
Smooth transition for employees and customers is a priority for both seller and buyers. The transaction is anticipated to close in H2 2021
Quote from Albert Today s announcement is the result of a comprehensive and robust selection process.
Capco and Envizage Announce Strategic Partnership
Partners will work together to bring benefits of Envizage advice engine to financial services firms and their customers globally
Capco, the global management and technology consultancy, and Envizage, the London-based analytics software provider, today announced a new partnership that will see the two companies working together to deliver the benefits of Envizage s simulation-based holistic advice engine for financial services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210128005152/en/
Matt Hutchins, Capco (Photo: Business Wire)
Established by three former Morgan Stanley partners, Envizage supports banks, insurers, pension funds and retail wealth and asset managers through its patented methodology and technology acquired from Morgan Stanley, which is a minority stakeholder in the company.
(2)
NextPharma Set to Acquire Two Lonza Sites Specialized in Lipid Oral Dosage Forms
Agreement initiates process for future acquisition of Lonza sites in Ploermel (FR) and Edinburgh (UK) allowing NextPharma to broaden technology offering into lipid finished dosage forms
Centers of excellence employing a total of 390 staff offer expertise in Lipid Oral Dosage Forms including softgels and liquid-filled hard capsules for the pharma and nutrition markets
Sustainable growth and people development a priority for both companies
A French version of this release is also available
Quote from Gordon Bates, President and Head of Small Molecules, Lonza: NextPharma is an established and well-respected company, with extensive experience in oral and topical finished dosage forms. As such, it is the ideal buyer given the technologies available at the Ploermel and Edinburgh sites. We are confident that the capabilities and experience at the two sites are a complementary fit with NextPharma s
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Arbor Biotechnologies and Lonza Enter into Gene Editing Technology Licensing Deal
Arbor Biotechnologies IncDecember 23, 2020 GMT
The new agreement will provide Lonza with access to Arbor’s gene editing technology
Quote from David Cheng, CEO of Arbor:
“Arbor’s differentiated gene editing technologies allow Lonza to manufacture the next generation of therapeutics. Arbor is committed to seeking and working with partners in this field to build an ecosystem for the research, development and manufacturing of biological and cellular therapies.”
BASEL, Switzerland and CAMBRIDGE, Mass., Dec. 23, 2020 (GLOBE NEWSWIRE) Arbor Biotechnologies and Lonza announced today a license agreement to provide Lonza with access to Arbor’s next-generation CRISPR-based gene editing technology. Lonza will have the ability to utilize Arbor’s proprietary technology in its bioproduction products and